Longevity Health Holdings Reports 21% Decline in Net Sales for Q2 2026

Longevity Health Holdings, Inc. reported a significant decline in financial performance for the second quarter of 2026, with net sales dropping to $395,991, a decrease of 21% from $503,612 in the same period of 2025. Gross sales also fell by 17% to $444,967, attributed primarily to reduced demand and increased competition in the bio-aesthetics market. The company's gross profit for the quarter was $235,536, down from $302,658 a year earlier. For the first half of 2026, net sales totaled $787,755, down 22% from $1,013,965 in the prior year, while gross profit decreased to $472,561 from $572,481.

The company’s operating expenses saw a notable reduction, totaling $959,686 for the second quarter, down 56% from $2,161,262 in the same quarter of 2025. This decrease was driven by cost efficiencies, including reductions in selling and marketing expenses, which fell by 45% to $191,438, and research and development expenses, which decreased by 68% to $73,351. General and administrative expenses also dropped significantly, from $1,564,967 to $681,559. Despite these reductions, Longevity Health reported a net loss of $1,883,290 for the quarter, slightly improved from a loss of $1,886,438 in the previous year.

In terms of strategic developments, the company completed the Elevai Acquisition in early 2025, which has been a focal point of its operations. The acquisition has led to the introduction of new products, although the company has faced challenges in product adoption and market penetration. As of June 30, 2026, the company had cash and cash equivalents of $35,471, a significant decrease from $706,740 at the end of 2025, reflecting ongoing liquidity challenges. The company also reported a negative working capital of $8,881,397, raising concerns about its ability to continue operations without additional financing.

Longevity Health's operational metrics indicate a need for improvement, with a decrease in customer engagement and product sales. The company is currently exploring options to raise additional capital through equity or debt financing to support its operations and alleviate liquidity concerns. The management has acknowledged that failure to secure additional funding could lead to further operational cutbacks. The company’s outlook remains cautious, with substantial doubt about its ability to continue as a going concern over the next 12 months unless it can successfully raise the necessary capital.

Overall, Longevity Health Holdings, Inc. is navigating a challenging financial landscape marked by declining sales, significant losses, and liquidity issues, while also attempting to integrate its recent acquisition and adapt to competitive pressures in the bio-aesthetics market.